AlveoliX offers organs-on-chip technology that recreates human organ micro-environments for more predictive preclinical drug testing. Their microfluidic systems enable assessment of drug safety, efficacy, and toxicity with greater human relevance, reducing late-stage failures in drug development.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional preclinical drug testing relies heavily on animal models and static in vitro assays, which often fail to accurately predict human physiological responses. This leads to high attrition rates in drug development, increased costs, and delays in bringing effective therapies to market.
Solution
AlveoliX provides advanced organs-on-chip technology that recreates complex human organ micro-environments, enabling more predictive preclinical testing. Our systems, including the AX Barrier-on-Chip and AX Lung-on-Chip, utilize microfluidic principles and dynamic mechanical stimulation to emulate in vivo conditions. This approach allows for the assessment of drug safety, efficacy, and toxicity with greater human relevance. By integrating these models into the drug discovery pipeline, AlveoliX aims to improve the predictability of preclinical data, thereby reducing late-stage failures and accelerating the development of personalized medicine.
Target Audience
Our primary customers are pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic research institutions involved in drug discovery and preclinical development.
Features
- Microfluidic chip design with an ultrathin, porous, and elastic membrane (3.5µm thickness, 3µm pores) for cell culture.
- Dynamic mechanical stimulation capabilities, including breathing motion (12 cycles/min, 8% linear strain) and customizable uni- or bidirectional membrane movement for barrier models.
- Support for mono- and co-culture models, including those with immune components, to replicate complex tissue interactions.
- Air-liquid interface design ideal for inhalation and exposure studies.
- Capability to model various tissue barriers beyond the lung, such as gut, skin, brain, and kidney.
- Pre-established toxicity and efficacy models, including monoculture, co-culture, immuno, inflammation, and fibrosis models.
- Custom model development services, allowing for tailored experimental designs and transfer to client laboratories.
- Compatibility with standard laboratory equipment for seamless integration into existing workflows.